Description
Semaglutide is a synthetic analog of the human glucagon-like peptide-1 (GLP-1), a hormone that plays a crucial role in glucose metabolism and appetite regulation. It is designed to mimic the effects of GLP-1, promoting insulin secretion in response to meals, inhibiting glucagon release, and slowing gastric emptying. Semaglutide is typically administered via subcutaneous injection. Its prolonged half-life allows for once-weekly dosing, making it convenient for patients. Semaglutide has gained attention for its effectiveness in managing type 2 diabetes and aiding in weight loss.
Medical use
Semaglutide is primarily used for the treatment of type 2 diabetes, where it helps improve glycemic control by enhancing insulin secretion and reducing blood sugar levels. In addition to its role in diabetes management, semaglutide has been studied for its potential in weight management. Clinical trials have demonstrated significant weight loss in individuals with obesity or overweight, making it a valuable option for those seeking to reduce body weight and improve metabolic health.
The medication works by promoting satiety, reducing appetite, and influencing food intake, which can lead to sustainable weight loss. Semaglutide has also shown potential cardiovascular benefits, including a reduction in the risk of major adverse cardiovascular events in patients with type 2 diabetes.
